DEA Begins Targeting Off-Label Prescribing of TIRF Products – Pain Medicine News – Oct 2017 – Ronald W. Chapman II, Esq.
TIRF = Transmucosal Immediate-Release Fentanyl
Traditionally, the decision whether to prescribe a certain medication off-label or not is reserved for the independent judgment of the physician and the specific needs of the patient.
Off-label uses of prescription medication are not regulated by the FDA and may be employed as long as the prescription is within the standard of care and is prescribed in the usual course of professional practice and for a legitimate medical purpose.
Recently, however, the Drug Enforcement Administration (DEA) has initiated criminal and administrative action against physicians who prescribe opioids, such as transmucosal immediate-release fentanyl (TIRF), off-label for the treatment of breakthrough pain. Continue reading
Misdiagnosing the Opioid Crisis | Cato Institute | By Jeffrey A. Singer | September 27, 2017
Here’s a doctor who truly understands that hounding doctors about opioid prescriptions is not only futile but harmful.
He outlines how outdated beliefs are driving our doomed and dangerous response to the “opioid overdose crisis”, pursuing policies that have been proven ineffective and even damaging.
Policymakers in Washington and in state capitals are misdiagnosing the opioid crisis as a doctor-patient problem.
Their policies are coming between doctors and patients. Continue reading
Promoting Pain Relief and Preventing Abuse of Pain Medications: A Critical Balancing Act – A joint statement from 21 health organizations and the Drug Enforcement Administration (DEA).
In this PDF file from October 2016, I found surprisingly patient-centered statements endorsed by the DEA, like:
“For many patients, opioid analgesics… are the most effective way to treat their pain, and often the only treatment option that provides significant relief.”
…share a responsibility for ensuring that prescription pain medications are available to the patients who need them
However, I don’t see any indication the DEA is following its own “consensus statement”. Continue reading
The DEA Is to Blame for America’s Opioid Overdose Epidemic | Foundation for Economic Education by Cathy Reisenwitz December 05, 2016
A record-breaking 28,000 Americans died of opioid overdoses in 2014.
The truth is that many of those deaths are completely preventable and result not from painkillers, but from the Drug Enforcement Administration’s war on painkillers.
A study in the Journal of the American Medical Association showed that half of all troops who return from Iraq and Afghanistan suffer from chronic pain.
Forcing Users into the Black Market
I would not assume that many patients are trying to find pain pills in the streets because many patients, like me, do not know where to get “street drugs”.
Why the DEA just said ‘no’ to loosening marijuana restrictions – The Washington Post
For the fourth consecutive time, the Drug Enforcement Administration has denied a petition to lessen federal restrictions on the use of marijuana.
While recreational marijuana use is legal in four states and D.C., and medical applications of the drug have been approved in many more, under federal law, it remains a Schedule 1 controlled substance, which means it’s considered to have “no currently accepted medical use” and a “high potential for abuse.”
The gap between permissive state laws and a restrictive federal policy has become increasingly untenable in the minds of many doctors, patients, researchers, business owners and legislators. Continue reading
Cannabinoid Receptor 2: Pain Treatment Without Tolerance or Withdrawal – reposted with edits from April 2015
This article about a promising new medicine derived from cannabis was published by the National Institute on Drug Abuse (NIDA), on their site “drugabuse.gov“. (Other branches of the same government, FDA and DEA, still classify cannabis as a Schedule I drug,)
Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal.
The treatment of cancer pain is often among the approved uses of medical cannabis in states where it is legal. Continue reading
Obtaining Adequate Data to Determine Causes of Opioid-Related Overdose Deaths | Pain Medicine – 1 June 2011
Current data collected by medical examiners and coroners are incomplete and inadequate to evaluate the factors that lead to fatalities involving prescription opioids.
Determining cause of death is critically important.
This issue is now 5 years old and nothing has been done.
Pinpointing the causes of opioid-related overdose deaths would show data that the anti-opioid zealots do not want to publicize: that most are caused by combinations of illegal drugs and very few by only prescribed opioids. Continue reading
DEA Wants Inside Your Medical Records to Fight the War on Drugs – The Daily Beast
The drug war has gone rogue.
The feds are fighting to look at millions of private files without a warrant, including those of two transgender men who are taking testosterone.
Marlon Jones was arrested for taking legal painkillers, prescribed to him by a doctor, after a double knee replacement.
Jones, an assistant fire chief of Utah’s Unified Fire Authority, was snared in a dragnet pulled through the state’s program to monitor prescription drugs after someone stole morphine from an ambulance in 2012. Continue reading
Details On Death Certificates Offer Layers Of Clues To Opioid Epidemic – June 1, 2016
Gill is the chief medical examiner for the state of Connecticut, and in the past two years, Gill’s office has seen a more than 50 percent increase in autopsies.
That’s mostly because of the spike in accidental drug overdoses, he said. Heroin is the big player. Fentanyl deaths have surged, too.
There’s another reason to get solid data — so you can craft a public health response to the epidemic.
Specificity about a death today could help save a life tomorrow, he says. Continue reading
Physician’s Guide to DEA Administrative Inspections – Pain Medicine News
This article was written for doctors and helps explain why so many of them are reluctant to prescribe opioids.
If you had to face this kind of government-mandated harassment, which could result in losing your ability to practice your profession, would you risk it?
The Drug Enforcement Administration (DEA) employs hundreds of Diversion Investigators to monitor compliance with the Controlled Substances Act (CSA).1 Principal methods for maintaining compliance and determining noncompliance are “inspections” or “audits,” which the DEA has the authority to conduct without a criminal warrant, as established by federal law outlined in the Code of Federal Regulations (CFR) Continue reading